Geron (GERN) is discontinuing its Phase 2 study of imetelstat in HER2-negative breast cancer...

|About: Geron Corporation (GERN)|By:, SA News Editor

Geron (GERN) is discontinuing its Phase 2 study of imetelstat in HER2-negative breast cancer because imetelstat performed worse than the control. It also says its Phase 2 study of imetelstat for lung cancer is unlikely to meet success. (PR)